File: '\\swfile\EmailIn\20241119 133432 Attachment 2024_11_19 ENBI NR proxy circular update.docx'

Entheon Biomedical Provides Information on Annual General Meeting Proxy Circular

VANCOUVER, BC, November 19, 2024 - Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") announces that, due to the Canada Postal Strike, there is a delay in the mailing of the Company's proxy circular and related documents pertaining to the Company's Annual General Meeting (the "Meeting") of the shareholders to be held virtually on Monday, December 16, 2024 at the hour of 10:00 a.m. (Pacific Time).

The Company advises that the documents may be found under the Company's profile on Sedar+. Additionally, shareholders may contact the Company directly at kelly@niacorporateservices.com to request the meeting material and to register votes via proxy.

The Company is conducting the Meeting virtually. Registered shareholders and validly appointed proxyholders may attend the Meeting via Zoom at:

https://us06web.zoom.us/j/81488611280?pwd=2H8cFjJHp6m9nvc9nYMQRnLb6s0Orz.1

Meeting ID: 814 8861 1280

Passcode: 127306

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,

Timothy Ko, CEO, President and Director

For more information, please contact the Company at:

Entheon Biomedical Corp.

Timothy Ko, CEO

timothy@entheonbiomedical.com

https://entheonbiomedical.com